Preview

Meditsinskiy sovet = Medical Council

Advanced search

Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

https://doi.org/10.21518/2079-701X-2019-19-16-21

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide. Despite the success over recent years in the treatment of NSCLC it has not yet been able to achieve good long-term survival. The development of immune checkpoint inhibitors has altered the landscape of treatment of advanced cancers, including non-small cell lung cancer (NSCLC). Nivolumab is the PD-1 inhibitor approved for the treatment of NSCLC to show a survival benefit in a randomised phase III trials. The experience of physicians in routine clinical practice is often different from those in a controlled clinical trial setting. The purpose of this analysis is to evaluate nivolumab use in real world setting. Results: The general survival at 76 patients by metastatic NSLC receiving an immunotherapy nivolumab during the period from 2015 to 2019 is analysed. The minimum time of observation was 1.6 months. The median of the general survival made 7.6 months (5.92-9.41. DI 95%). The one-year survival - 35%, at the same time 3-year survival was 25%. At patients with the objective answer the median of the general survival was not reached. Immunomediated adverse events developed in 42% of patients, but only 6.6% showed the development of adverse events of 3-4 degrees, which indicates a favorable toxicity profile. Conclusion: the results received by us correlate with data of clinical trials.

About the Authors

K. K. Laktionov
Federal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation

Dr. of Sci. (Med), Professor, Head of the Department of Chemotherapy No.1 of the Thoraco-Abdominal Department

23, Kashirskoye sh., Moscow, 115478, Russia



K. A. Sarantseva
Federal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation

Cand. of Sci. (Med), Oncologist

23, Kashirskoye sh., Moscow, 115478, Russia 



D. I. Yudin
Federal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation

Cand. of Sci. (Med), Senior Researcher

23, Kashirskoye sh., Moscow, 115478, Russia 



V. V. Breder
Federal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation

Dr. of Sci. (Med), Leading Researcher

23, Kashirskoye sh., Moscow, 115478, Russia 



E. V. Reutova
Federal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation

Cand. of Sci. (Med), Senior Researcher

23, Kashirskoye sh., Moscow, 115478, Russia 



K. P. Laktionov
Federal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation

Dr. of Sci. (Med), Professor, Leading Researcher

23, Kashirskoye sh., Moscow, 115478, Russia 



References

1. Gettinger S., Horn L., Jackman D. at al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study. Journal of Clinical Oncology 2018;36(17):JCO2017770412.·doi: 10.1200/JCO.2017.77.0412.

2. Horn L., Spigel D.R., Vokes E.E., Holgado E., Ready N., Steins M. et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: TwoYear Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924-3933. doi:. 10.1200/JCO.2017.74.3062

3. Reck M., Taylor F., Penrod J.R., DeRosa M., Morrissey L., Dastani H., Orsini L., Gralla R.J. Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study. J Thorac Oncol. 201813(2):194-204. doi: 10.1016/j.jtho.2017.10.029.

4. Laktionov, K.K., Sarantseva K.A., Breder V.V., Reutova E.V., Yudin D.I., Laktionova L.V. Results of nivolumab use in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Cancer Research Center. Voprosy oncologii = Problems in oncology2017;63(5):724-728. (In Russ.)

5. Laktionov K.K., Sarantseva K.A., Breder V.V., Okruzhnova M.A., Peregudova M.V. Immunotherapy for non-small cell lung cancer treatment. Zlokachestvennye opukholi = Malignant tumours. 2016;(3):17-24. (In Russ.) doi: 10.18027/2224-5057-2016-3-17-24.

6. Burstein H.J., Krilov L., Aragon-Ching J.B., Baxter N.N., Chiorean E.G., Chow W.A. et al. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017;35(12):1341-1367. doi: 10.1200/JCO.2016.71.5292.

7. Chae Y.K., Pan A., Davis A.A., Raparia K., Mohindra N.A., Matsangou M., Giles F.J. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cacer:Is PD-L1 Expression a Good Marker for Patient Selection? Clin Lung Cancer. 2016;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011.


Review

For citations:


Laktionov KK, Sarantseva KA, Yudin DI, Breder VV, Reutova EV, Laktionov KP. Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center. Meditsinskiy sovet = Medical Council. 2019;(19):16-21. (In Russ.) https://doi.org/10.21518/2079-701X-2019-19-16-21

Views: 540


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)